Skip to main content
  • Preventative PCI with Optimal Medical Therapy Reduces Long-Term MACE in Patients with Non-Flow-Limiting Vulnerable Plaques: PREVENT Trial

    Long-term major adverse cardiac events (MACE) are reduced in patients with non-flow-limiting vulnerable plaques who undergo preventative percutaneous coronary intervention (PCI) plus optimal medical therapy, compared with only optimal medical therapy, the PREVENT trial shows.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details